Cannaponics has said it is making substantial progress in the construction of a 3,600-sqm greenhouse facility near Collie, WA in readiness for the harvest of its first crop within the next 12 months.
The greenhouse building will be completed by the end of April, with the first crop to be planted before the end of the year.
Managing director of the vertically integrated medicinal cannabis company Rod Zakostelsky said more than 15 jobs have been created to support the construction phase, with more to follow.
Levin Health has appointed Dr James Stewart and Dr Debbie Herbst to its recently formed Medical Advisory Board.
Stewart – named Doctor of the Year and People’s Choice Award winner at the 2021 Australian Cannabis Industry Awards – and experienced medicinal cannabis prescriber Herbst join Professor Bruce Mitchell and Dr Harry Unglik, who were appointed to the board in late 2021.
Mitchell is chair of Monash Clinical Research and the Sports Medicine Australia Research Foundation and a board member of the Pain Research Foundation.
Unglik has 40 years’ experience as a doctor, including stints with the Australian Olympic team, North Melbourne AFL Club and Melbourne Sports Medicine Centre.
Creso Pharma’s Canadian psychedelics company Halucenex Life Sciences expects its first psilocybin mushroom harvest within the next three months.
Creso said upgrades to the firm’s grow room in Nova Scotia are complete, including a high-performance liquid chromatography (HPLC) system which will be used to test the active pharmaceutical ingredients in both synthetic and botanical psilocybe mushrooms.
It plans to use the first harvest for research and development and product development purposes.
Creso Pharma managing director and CEO William Lay said: “The successful commissioning of the HPLC system will allow the group to gain a detailed understanding of botanical and synthetic psilocybin content and purity.
“The recent renovations to the company’s grow room are an important milestone ahead of our first planned harvest. The initiative has laid a strong foundation to commence cultivation, which will provide cost-effective biomass for R&D purposes.”
InhaleRx has received licences to wholesale schedule 2, 3 and 4 medications, in addition to a limited number of schedule 8 medications, including medicinal cannabis.
Executive director Darryl Davies said the granting of the licences by the Victorian Department of Health was “an important milestone” for the company.
The development will see InhaleRX store and distribute medications using accredited third-party logistics suppliers to authorised recipients across Australia.
“Given this development, the company can now take ownership of scheduled medications, which creates possibilities for new product development and associated revenue streams,” he said.
The Sustainable Nutrition Group
Hemp manufacturer The Sustainable Nutrition Group has reported “positive results” as it continues the development phase of hemp isolates and concentrates.
The products, which are being developed in partnership with Australian Plant Proteins (APP), are expected to generate new revenue streams at “attractive margins”, the company said.
It said protein extraction from whole-seed hemp cake has achieved a protein level of more than 85%, exceeding that of soy bean, pea and faba bean protein concentrates.
The Sustainable Nutrition Group said products are expected to be commercialised in early FY23.
“The products are expected to be sold into the rapidly expanding plant-based food and beverage markets, including milks, yogurts, meat alternatives, protein bars and shakes, baked goods, protein supplements as well as sauces and condiment producers,” the firm added.